B cells and the Boob Part II

B

So I have taken a bit of a kicking, as I rightly did not comment on the long-term experience with rituximab in non-MS conditions and cancer is not a particular problem, so I do not want to scare you. However I can go back to ocrelizumab and give you thier take and the risks of cancer are small and that is the case for Breast cancer too. As you can see in many ways the risks are no different from life.

In brief this shows that there risks of cancer are small and similar to “Life”

CoI Multiple and I have done talks for Roche,

About the author

MouseDoctor

5 comments

  • Isn’t it necessary to bear in mind that therapy for cancer is in many cases neurotoxic, so potentially a greater risk in terms of consequences for people with CNS impairment / disease such as MS?

  • Huh? Wha?

    As a partner of a young person who had genetically associated breast cancer and then MS… what are you trying to say about the risk for people with a pre-disposition to breast caner on long term ocrelizumab therapy and its effect?

    That the risk of cancer is small and similar to life? – we played those odds, we lost the odds with an aggressive breast cancer diagnosis at the age of 30… what now?

    What are her odds (not standardised odds) if she spends the next 10 years on ocrelizumab?

    4 years after the HSCT treatment and I’m still scouring the internet and barts’ blog for an answer… and i’m still not getting it. Any news?

  • This “similar to life” statement makes no sense.

    Similar to what life? To a life of occasional smoking, regular binge drinking and living in an area with high air pollution?

    Or a low stress life in a rural area eating health food, exercising regularly, surrounded by fresh air?

    Smacks of a post to appease those profiting from ocrelizumab.

By MouseDoctor

Translate

Categories

Recent Posts

Recent Comments

Archives